Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.59 USD | -2.13% | +3.49% | +10.87% |
Mar. 19 | Transcript : Relmada Therapeutics, Inc., 2023 Earnings Call, Mar 19, 2024 | |
Mar. 19 | Relmada Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 3M | Capitalization | 138M |
---|---|---|---|---|---|
Net income 2024 * | -112M | Net income 2025 * | -120M | EV / Sales 2024 * | - |
Net cash position 2024 * | 203M | Net cash position 2025 * | 124M | EV / Sales 2025 * | 4.89 x |
P/E ratio 2024 * |
-1.5
x | P/E ratio 2025 * |
-1.95
x | Employees | 20 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.76% |
Latest transcript on Relmada Therapeutics, Inc.
1 day | -2.13% | ||
1 week | +3.49% | ||
Current month | -25.06% | ||
1 month | -22.60% | ||
3 months | +8.77% | ||
6 months | +45.71% | ||
Current year | +10.87% |
Managers | Title | Age | Since |
---|---|---|---|
Paolo Manfredi
FOU | Founder | 62 | 12-05-30 |
Sergio Traversa
CEO | Chief Executive Officer | 63 | - |
Maged Shenouda
DFI | Director of Finance/CFO | 59 | 15-11-11 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 78 | 15-07-13 | |
Sergio Traversa
CEO | Chief Executive Officer | 63 | - |
Maged Shenouda
DFI | Director of Finance/CFO | 59 | 15-11-11 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.10% | 0 M€ | 0.00% | - | |
0.03% | 464 M€ | -.--% | ||
0.00% | 227 M€ | +4.45% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-27 | 4.59 | -2.13% | 149,749 |
24-03-26 | 4.69 | -4.29% | 103,407 |
24-03-25 | 4.9 | +0.82% | 271,608 |
24-03-22 | 4.86 | +4.29% | 267,518 |
24-03-21 | 4.66 | +5.07% | 651,901 |
Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.87% | 138M | |
+2.56% | 108B | |
+10.02% | 104B | |
+8.12% | 23.66B | |
-11.91% | 22.1B | |
-3.29% | 19.71B | |
-35.98% | 18.2B | |
-14.02% | 16.19B | |
+4.61% | 13.72B | |
+35.05% | 12.22B |